Ads
related to: glp 1 agonist small molecule- GLP-1 Nutrition Support
Maximize Your Benefits By Pairing
Medication With OPTAVIA® Program.
- 4 & 2 Active Plan™
Helps You Reach Optimal Health -
Adding Movement To Your Routine.
- Set Healthy Intentions
Leave Quick Fixes Behind
Commit To Mastering Weightloss
- Find Your Customized Plan
OPTAVIA® Offers Weight Loss Plans
Tailored To Your Health Needs.
- GLP-1 Nutrition Support
Search results
Results From The WOW.Com Content Network
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. [1] It is delivered orally and is in a Phase II trial as of 2023.
Attempts to develop an orally bioavailable GLP-1 agonist, either a modified peptide, as in the case of oral semaglutide, [34] or a small molecule drug, have produced additional drug candidates. [26] Other companies have tested inhaled or transdermal administration.
Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] [2] It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper. [3]
GLP-1 agonists are a class of medications that mimic the action of the hormone GLP-1 (glucagon-like peptide-1), which is involved in insulin production and appetite regulation. “GLP-1 stands for ...
GSBR-1290 is an orally-available, nonpeptide small molecule glucagon-like-peptide-1 receptor (GLP-1R) agonist that has demonstrated competitive weight loss and generally favorable safety and tolerability results in previous studies with once-daily dosing.
In accordance with the expression of GLP-1 receptor on brainstem and hypothalamus, GLP-1 has been shown to promote satiety and thereby reduce food and water intake. Consequently, diabetic subjects treated with GLP-1 receptor agonists often experience weight loss as opposed to the weight gain commonly induced with other treatment agents. [2] [15]
Ad
related to: glp 1 agonist small molecule